Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pain-free microneedle influenza vaccine effective, long-lasting

By Drug Discovery Trends Editor | September 5, 2013

Scientists have developed an influenza vaccine delivered via microneedle patch that provided 100% protection against a lethal influenza virus in mice more than one year after vaccination.  They report their findings in the September 2013 issue of the journal Clinical and Vaccine Immunology.

Microneedles are a medium for delivery of influenza vaccine that avoids the pain associated with ordinary hypodermic needles. They are a mere seven tenths of a millimeter in length, and the volume of vaccine—a major contributor to pain—is minuscule.

Instead of a liquid containing whole killed or attenuated virus, this vaccine uses dry virus-like particles (VLPs) which simply coat the needles in the presence of a simple stabilizing agent, reducing the need for refrigeration—a potential boon for use in developing countries. The lower dose required when using microneedles also reduces the potential for side effects, such as lung inflammation.

“This method can induce higher levels of IgG2a antibodies as well as rapid recall immune responses following lethal challenge infection. Our previous study showed that microneedle vaccination induced higher levels of antibody-secreting cells in spleen and bone marrow compared to intramuscular vaccination,” says Sang-Moo Kang of Georgia State University, a researcher on the study.

Earlier studies by this group showed that influenza VLP-coated microneedles actually produced higher short-term protection than conventional intramuscular immunization.  In this study the researchers tested how effective the long-term protection of the vaccine was.  Mice that received the vaccine were 100 percent protected from a lethal challenge with the influenza virus 14 months after vaccination.

Kang says his aim was to develop an easier and pain-free method of vaccine delivery. He also says that patients could probably use this system to vaccinate themselves.

Long-term protective immunity from an influenza virus-like particle vaccine administered by a microneedle patch

Source: American Society for Microbiology


Filed Under: Drug Discovery
Tagged With: microneedle influenza vaccine
 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE